An ultrasensitive fluorescence sensing platform for HCV detection based on the T7 isothermal amplification combined with aggregation-induced emission luminogens strategy

Abstract

Hepatitis C virus infection constitutes a significant global public health concern. Fluorescence technique (FL) is a promising biosensor, however, many conventional dyes exhibit reduced fluorescence or no emission at high concentrations. To break through this shackle, an ultrasensitive AIE-based (aggregation-induced emission) FL sensing platform was developed for HCV detection by using the FLRNAs-based T7 isothermal transcription amplification RNA diagnosis combined with AIE luminogens (FTAR) strategy. In the FTAR strategy, the T7 transcription amplification process was responsible for the recognition of the target HCV and produced Pepper aptamer, which could form aggregates of nanoparticles with the HBC, an AIEgen, to produce high-intensity FL. The multi-integrated signal amplification strategy led to ultrasensitivity. Moreover, under the optimal experimental conditions, HCV could be assayed in the range of 100aM-100pM. The proposed strategy has been successfully applied in detecting HCV in clinical samples. In summary, this research was the first to utilize aptamer restriction of AIEgens internal rotation to achieve aggregation-induced emission and presented the successful development of a specific, sensitive and rapid FTAR assay for HCV diagnosis. The proposed FTAR platform with facile operation, short analysis time, low-cost as well as excellent quantification ability could provide a promising tool for point-of-care testing (POCT).